AZN · Pharma and healthcare · one day
AstraZeneca (AZN): news on Friday 30 October 2026
News from the 24 hours to Friday morning, 30 October 2026.
Tone of the day
What the score means. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Why it scored this way
Coverage was mostly positive, centred on EU approval for Enhertu, successful late-stage trial results for TEZSPIRE and in gastric cancer, and new AI and drug discovery partnerships. Shares edged higher ahead of upcoming quarterly results.
What drove it
- clinical trial results
- EU Enhertu approval
- AI partnerships
Around this day
| Day | Tone | Headlines |
|---|---|---|
| Sat 24 Oct | +9.2 | 8 |
| Sun 25 Oct | +10.0 | 16 |
| Mon 26 Oct | +10.0 | 33 |
| Tue 27 Oct | +9.2 | 35 |
| Wed 28 Oct | +7.5 | 33 |
| Thu 29 Oct | +2.8 | 13 |
| Fri 30 Oct | +6.3 | 13 |
9 stories · 13 headlines · strongest first
Pharma and healthcare on 30 OctoberFTSE 100 that day| Tone | What the article reported, and why it scored that way | |
|---|---|---|
| AstraZeneca Q3 results preview for 30 October +2.93 headlines today · 10 in all, since 24 October · Previews ahead of third-quarter results discuss revenue estimates and oncology momentum. | ||
| +3.3 | Results preview with valuation suggesting room for share gains. | |
| +2.5 | Results preview questioning whether cancer drug growth continues. | |
| +1.7 | Preview of upcoming results with sizeable revenue expectations. | |
| EU authorises Enhertu after surgery in patients with HER2-positive early-stage breast cancer +9.52 headlines today · 12 in all, since 28 October · Articles discuss the EU approval of Enhertu for early breast cancer and investor reaction. | ||
| +8.3 | European regulatory clearance for a breast cancer treatment widens its use. | |
| +8.3 | EU approval for a key cancer drug. | |
| Mark-Paul Gosselaar and AstraZeneca begin Meet Your Mark cancer biomarker testing campaign +2.72 headlines today · 4 in all, since 29 October · Coverage continues of the biomarker testing campaign fronted by Mark-Paul Gosselaar. | ||
| +2.5 | Awareness campaign supporting biomarker testing for patients. | |
| +0.8 | Marketing campaign launch while shares trade sideways. | |
| Phase III: AstraZeneca's sone-ve gives gastric cancer patients twice the survival +9.81 headline today · 30 in all, since 26 October · A report covers a gastric cancer trial showing a 42% lower death risk. | ||
| +10.0 | Strong survival benefit shown in gastric cancer trial. | |
| Tezspire succeeds in Phase III trial, AstraZeneca and Amgen say +10.01 headline today · AstraZeneca and Amgen reported positive Phase III results for Tezspire. | ||
| +10.0 | Late-stage trial success with partner for a respiratory medicine. | |
| Oracle and AstraZeneca team up +5.81 headline today · A piece looks at why Oracle is working with AstraZeneca. | ||
| +5.8 | Technology partnership with a major software firm, positive collaboration signal. | |
| AstraZeneca and Tremont AI to build preclinical drug safety models +5.01 headline today · AstraZeneca and Tremont AI plan to develop artificial intelligence models covering preclinical drug safety. | ||
| +5.0 | AI collaboration aimed at improving early safety testing of drug candidates. | |
| AstraZeneca shares rise on Thursday +5.01 headline today · AstraZeneca shares advanced and outperformed the market. | ||
| +5.0 | Shares rose and beat the broader market. | |
| AstraZeneca partners with Insitro on drug discovery +5.01 headline today · A piece asks whether the Insitro tie-up can speed up drug discovery. | ||
| +5.0 | New discovery partnership could speed up research. | |
Each article has its own score. The lines are our own summary; follow the source link to read the article itself.
Follow by email
A short, free morning email on how the news treated AstraZeneca: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.